About Zentalis

We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Using our unique chemistry and biological expertise, we have developed an integrated approach to identify and overcome the limitations of current cancer therapeutics, enabling us to design better small molecules for improved patient outcomes.

Learn More

Pipeline

CompoundComp
IndicationInd
Development ApproachDev
PreclinicalPre
Early Clinical DevelopmentEarly
Late Clinical DevelopmentLate
Azenosertib
(ZN-c3)
Wee1 Inhibitor
Uterine Serous Carcinoma
Monotherapy
Uterine Serous Carcinoma
Monotherapy
Solid Tumors
Monotherapy
Solid Tumors
Monotherapy
Cyclin E Driven High Grade Serous Ovarian
Monotherapy
Cyclin E Driven High Grade Serous Ovarian
Monotherapy
PARP Resistant Ovarian Cancer
Monotherapy alternating with niraparib or concurrent with niraparib
PARP Resistant Ovarian Cancer
Monotherapy alternating with niraparib or concurrent with niraparib
Ovarian Cancer
+ Multiple Chemotherapy Backbones
Ovarian Cancer
+ Multiple Chemotherapy Backbones
Osteosarcoma
+ gemcitabine
Osteosarcoma
+ gemcitabine
BRAF Mutant mCRC
+ encorafenib and cetuximab
BRAF Mutant mCRC
+ encorafenib and cetuximab
Pancreatic Cancer
+ gemcitabine
Pancreatic Cancer
+ gemcitabine
ZN-d5
BCL-2 Inhibitor
AL Amyloidosis
Monotherapy
AL Amyloidosis
Monotherapy
NHL
Monotherapy
NHL
Monotherapy
AML
+ azenosertib
AML
+ azenosertib
BCL-xL
Degrader
Solid Tumors and Heme Malignancies
Solid Tumors and Heme Malignancies

Learn More

Join Zentalis